<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111094</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 122/19</org_study_id>
    <nct_id>NCT04111094</nct_id>
  </id_info>
  <brief_title>DKK3 for Prognosis and Monitoring of GFR Loss in Heart Failure</brief_title>
  <official_title>Urinary Dickkopf-3 for Prognosis and Monitoring of Glomerular Filtration Rate Loss in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The individual course of chronic kidney disease (CKD) may vary, and improved methods for
      identifying which patients will experience estimated glomerular filtration rate (eGFR) loss
      are needed. Recently, urinary dickkopf-3 (DKK3) has been proposed to predict eGFR loss in
      patients with CKD, independent of presence of albuminuria. The investigators sought to
      examine the association between DKK3 and loss of eGFR in patients with heart failure (HF).
      The investigators hypothesized that changes in DKK3 under treatment may be helpful to monitor
      individual kidney disease course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The individual course of chronic kidney disease (CKD) may vary, and improved methods for
      identifying which patients will experience estimated glomerular filtration rate (eGFR) loss
      are needed. Recently, urinary dickkopf-3 (DKK3) has been identified as a stress-induced,
      renal tubular epithelia-derived, secreted glycoprotein that induces tubulointerstitial
      fibrosis. Urinary DKK3 has been found to predict eGFR loss in patients with CKD, independent
      of presence of albuminuria. The investigators sought to examine the association between DKK3
      and loss of eGFR in patients with heart failure (HF). Also, the investigators hypothesized
      that changes in DKK3 under treatment may be helpful to monitor individual kidney disease
      course.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">October 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 13, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR loss</measure>
    <time_frame>12 months</time_frame>
    <description>eGFR (CKD-Epidemiology Collaboration equation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of tubular proteinuria with DKK3</measure>
    <time_frame>12 months</time_frame>
    <description>alpha 1 microglobulin/creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent or worsening of HF</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular death, hospital admission for decompensated HF, or clinical HF decompensation without hospital admission (but requiring parenteral HF therapy or changes in oral HF medications including diuretics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Requirement of incident renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of venous congestion with DKK3</measure>
    <time_frame>12 months</time_frame>
    <description>b-type natriuretic peptide, clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of right and left ventricular function with DKK3</measure>
    <time_frame>12 months</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Heart Failure</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>HF</arm_group_label>
    <description>Diagnosed heart failure as described by recent guidelines. Inclusion criteria will be applied: i) minimum one symptom typical of HF: positive physical examination (e.g., bilateral oedema, increased jugular pressure) or positive clinical history (e.g., orthopnoea, history of coronary vascular disease, history of arterial hypertension, exposition to cardiotoxic drug/radiation, diuretic use); b-type natriuretic peptide (BNP) or N-terminal pro-BNP levels ≥35 or ≥125 pg/ml, respectively; and iii) classification as New York Heart Association (NYHA) functional class 2 or 3. There is no prespecified inclusion criterion with respect to left ventricular ejection fraction as congestive symptoms and prevalence of kidney dysfunction are comparable in patients with HF across the left ventricular ejection fraction spectrum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes</arm_group_label>
    <description>Diagnosed diabetes mellitus, with/without treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertension</arm_group_label>
    <description>Diagnosed hypertension, with/without treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Diabetes</arm_group_label>
    <arm_group_label>HF</arm_group_label>
    <arm_group_label>Hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients ≥18 years of age with diagnosed HF or diabetes or hypertension
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients ≥18 years of age with diagnosed HF or diabetes or hypertension

        Exclusion Criteria:

          -  CKD stage with estimated GFR &lt;15 ml/min/1.73 m2

          -  pre-existing acute kidney injury

          -  non-end stage renal disease with extracorporeal or peritoneal ultrafiltration due to
             diuretic-resistant fluid overload

          -  pre-diagnosed glomerulonephritis

          -  pyelonephritis

          -  autosomal dominant polycystic kidney disease

          -  postrenal obstruction

          -  active tumor disease

          -  inflammatory or autoimmune disease requiring systemic immunosuppressive treatment

          -  serum high-sensitivity C-reactive protein &gt;20mg/l

          -  recipients of solid-organ transplants

          -  patients who received non-steroidal anti-inflammatory drugs or intravenous contrast
             media within 72 hours prior to recruitment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Seeger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Giessen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faeq Husain-Syed, MD</last_name>
    <phone>004964198542378</phone>
    <email>faeqhusain@yahoo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Horst-Walter Birk, MD</last_name>
    <phone>004964198542378</phone>
    <email>horst-walter.birk@innere.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic Giessen and Marburg - Campus Giessen</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faeq Husain-Syed, MD</last_name>
      <phone>+49 641 985 42378</phone>
      <email>faeqhusain@yahoo.de</email>
    </contact>
    <contact_backup>
      <last_name>Horst-Walter Birk, MD</last_name>
      <phone>+49 641 985 4278</phone>
      <email>horst-walter.birk@innere.med.uni-giessen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Zewinger S, Rauen T, Rudnicki M, Federico G, Wagner M, Triem S, Schunk SJ, Petrakis I, Schmit D, Wagenpfeil S, Heine GH, Mayer G, Floege J, Fliser D, Gröne HJ, Speer T. Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. J Am Soc Nephrol. 2018 Nov;29(11):2722-2733. doi: 10.1681/ASN.2018040405. Epub 2018 Oct 2.</citation>
    <PMID>30279273</PMID>
  </reference>
  <reference>
    <citation>Federico G, Meister M, Mathow D, Heine GH, Moldenhauer G, Popovic ZV, Nordström V, Kopp-Schneider A, Hielscher T, Nelson PJ, Schaefer F, Porubsky S, Fliser D, Arnold B, Gröne HJ. Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight. 2016 Jan 21;1(1):e84916. doi: 10.1172/jci.insight.84916.</citation>
    <PMID>27699213</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

